A Genuinely Difficult Screening Decision
Unlike many cancer screenings with relatively clear-cut recommendations, PSA testing for prostate cancer remains a genuinely contested area of medicine, with reasonable experts disagreeing about optimal screening strategy. This is not a case of outdated guidelines lagging behind clear evidence, but a situation where the evidence itself reveals real trade-offs that make a single universal recommendation difficult to justify.
The Core Tension
PSA screening can detect prostate cancer earlier, potentially improving outcomes for aggressive cancers caught before spread. But prostate cancer also includes many slow-growing forms that would never have caused symptoms or death if left undetected, and screening cannot reliably distinguish dangerous from indolent cancers, leading to overdiagnosis and overtreatment — including surgery and radiation with real side effects like incontinence and erectile dysfunction — for cancers that posed no genuine threat.
Making an Individualized Choice
Current guidelines generally recommend shared decision-making, where men discuss their individual risk factors, including family history and race, since Black men face higher prostate cancer risk, alongside personal values about the trade-off between potential early detection benefit and overdiagnosis risk, rather than a uniform recommendation for or against screening. This individualized approach respects that the right answer genuinely differs based on personal risk and values. Facilities can source diagnostic equipment and lab supplies from our catalog.
